Interim report, foreign filer
Open the filing on sec.gov
Immatics N.V. (IMTX)
Nasdaq: IMTX · Biological Products, (No Diagnostic Substances) · Tubingen, DE · filing with the SEC since 2020
The companyfiscal 2025, as filed
Revenuen/a
Net income-€196M-1390.9%
Earnings per share€-1.61-1250.0%
Operating cash flow-€177M-11.8%
Cash€346M+46.1%
Debtn/a
Shareholders’ equity€484M-15.8%
Shares, diluted122.3M+15.7%
Return on equity-40.6%
The recordfrom its filings
Filings in 202655
Newest filingNov 10 · 6-K
Annual reportMar 5, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$7.5M
Patents grantedn/a
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in EUR. Nothing here is a forecast.
News
Moderna raises its 2026 revenue outlook after a third-quarter profit
Read the article
Interim report, foreign filer
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Activist holder update, amended
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Offering prospectus, notes or structured products
Open the filing on sec.gov
Interim report, foreign filer
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.